CanSino Biologics Inc. (6185) announced a proposal to use reserves to cover its parent company’s accumulated losses as of December 31, 2024. According to the 2024 annual financial statements, the parent company had losses totaling RMB1,450,342,128.90, a surplus reserve of RMB118,388,703.29, and a capital reserve of RMB6,576,729,725.03.

The plan involves using RMB118,388,703.29 from the surplus reserve and RMB1,331,953,425.61 from the capital reserve to fully offset the RMB1,450,342,128.90 in accumulated losses. Upon completion, the surplus reserve will be reduced to zero, and the capital reserve will stand at RMB5,244,776,299.42.

This proposal was approved at the third extraordinary meeting of the third session of the Board of Directors on November 7, 2025, and will be submitted for shareholder approval at the 2025 second extraordinary general meeting. The company indicates that this move aims to support high-quality development and enhance its capacity to deliver investor returns.